My Companies
Notification
Account
Log Out
Login
EDQM approved Wanbury’s new Rivaroxaban API, enabling sales in the EU and other CEP-accepting markets. USFDA also cleared Paroxetine HCl and Metformin HCl DMFs while reviewing multiple customer ANDAs, supporting regulatory expansion and potential future commercialisation.
Wanbury Tanuku Facility Receives USFDA Form 483 With Six Observations
Wanbury Board Approves Early Redemption of ₹180 Crore NCDs
Wanbury Trustee Releases 24.39% Pledge on Expert Chemicals Holding